New Antituberculosis Drugs: From Clinical Trial to Programmatic Use

Treatment of multidrug-resistant tuberculosis (MDR-TB) cases is challenging because it relies on second-line drugs that are less potent and more toxic than those used in the clinical management of drug-susceptible TB. Moreover, treatment outcomes for MDR-TB are generally poor compared to drug sensit...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Infectious Disease Reports Ročník 8; číslo 2; s. 6569
Hlavní autori:	Gualano, Gina, CAPONE, Susanna, MATTEELLI, Alberto, Palmieri, Fabrizio
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Italy MDPI AG 24.06.2016 PAGEPress Publications, Pavia, Italy
Predmet:	antituberculosis therapy Carbapenems Clinical outcomes Clinical trials Conversion Drug resistance Drugs Health services Linezolid Multidrug resistance Multidrug resistant organisms Multidrug-resistant Multidrug-resistant; antituberculosis therapy; new drugs; tuberculosis new drugs Nitroimidazole Other systems of medicine Review RZ201-999 Sputum Tuberculosis Multidrug-resistant antituberculosis therapy new drugs tuberculosis
ISSN:	2036-7449, 2036-7430, 2036-7449
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!